What’s Next in Neuroscience R&D? Panel Discussion at Upcoming BIO International Convention

Neuroscience R&D

Neuroscience disorders represent a sizable unmet therapeutic need, but long development timelines and low chances of success have caused biopharma companies to cut investment in this arena.  Now a better understanding of disease biology and a willingness to access expertise through partnerships have brought about a resurgence in neuroscience R&D. The fruits of this resurgence can’t come too soon. With central nervous system disorders on the rise as populations age — dementia rates are expected to quadruple by 2050 — there is a dire need for new drugs.

On June 16 during the BIO International Convention, WuXi’s SVP of International Discovery Service Unit, Dr. Richard Soll, will host a panel session “The Revitalization of Neuroscience R&D” to discuss new trends in neuroscience R&D and their implications for patients and society.  The panelists include Kees Been, Founder, President and CEO of Lysosomal Therapeutics Inc.;  Steve Kanes, CMO of Sage Therapeutics; Gerhard Koenig, SVP of Research and CSO of Forum Pharmaceuticals; and Todd Sherer, CEO of The Michael J. Fox Foundation.

The BIO International Convention, to be held in Philadelphia June 15 – 18, attracts more than 15,000 scientists, biotech leaders and entrepreneurs to provide insights and inspirations on major trends in the industry. For more information about this session, visit https://mybio.org/event/member/162827.

WuXi’s VP of Corporate Alliances, Dr. Hui Cai, will host another panel session at BIO called “Demystifying Product Development and Market Access in China and Asia”.  Click here to read more about it.

Subscribe to WXPress

Receive our newsletter and information on upcoming events.